Regulatory T cell epitopes, compositions and uses thereof

Inventors

De Groot, Anne • Martin, William • Rivera, Daniel S.

Assignees

Epivax Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11045532-B2

Patent

Publication Date

2021-06-29

Expiration Date


Abstract

The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.

Core Innovation

The invention provides chimeric polypeptides comprising first and second polypeptide chains linked together. The first polypeptide chain is a fragment of an immunoglobulin consisting of the amino acid sequence of SEQ ID NO: 23, and the second polypeptide chain comprises a biologically active molecule that is not an immunoglobulin polypeptide.

The document further describes regulatory T-cell engagement using T-cell epitope compositions derived from human proteins, including immunoglobulin-derived peptides. These compositions engage natural regulatory T cells via MHC class II and specific TCRs, and induce regulatory phenotypes characterized by CD4+CD25+FOXP3. The compositions increase IL-10 and TGF-β while suppressing effector cytokines such as IFN-γ and IL-4/IL-5.

The document also describes compositions and constructs that combine the regulatory T-cell epitope concept with biologically active payloads through linked chimeric formats. Examples include a Tregitope fusion construct with FVIII and enhanced vaccine delivery Fc constructs with modified Tregitopes, together with isolated T-cell epitope polypeptides selected from defined SEQ ID NO ranges and linkage variants attaching the second polypeptide chain to the N-terminus or C-terminus of the immunoglobulin fragment.

Claims Coverage

The document contains two independent claims. The core coverage centers on a two-chain chimeric polypeptide in which an immunoglobulin fragment (SEQ ID NO: 23) is linked to a non-immunoglobulin biologically active molecule, with optional inclusion of defined isolated T-cell epitope polypeptides and linkage orientation refinements.

Two-chain chimeric polypeptide with immunoglobulin fragment and non-immunoglobulin biologically active molecule

A chimeric polypeptide comprising a first and a second polypeptide chain linked together, wherein the first polypeptide chain is a fragment of an immunoglobulin consisting of the amino acid sequence of SEQ ID NO: 23, wherein the second polypeptide chain comprises a biologically active molecule, and wherein the biologically active molecule is not an immunoglobulin polypeptide.

Inducing regulatory T-cells suppression by administering chimeric polypeptide

A method of inducing regulatory T-cells to suppress immune response in a subject comprising administrating to the subject a therapeutically effective amount of a chimeric polypeptide, wherein the chimeric polypeptide comprises a first and a second polypeptide chain linked together, wherein the first polypeptide chain is a fragment of an immunoglobulin consisting of the amino acid sequence of SEQ ID NO: 23, wherein the second polypeptide chain comprises a biologically active molecule, and wherein the biologically active molecule is not an immunoglobulin polypeptide.

Overall claim coverage ties regulatory T-cell suppression to a chimeric polypeptide architecture that links an immunoglobulin fragment (SEQ ID NO: 23) to a non-immunoglobulin biologically active molecule, with dependent claim refinements to specify payload categories, fusion orientation (N-terminus or C-terminus), and optional inclusion of isolated T-cell epitope polypeptides defined by SEQ ID NO ranges.

Stated Advantages

Suppress immune response in a subject via inducing regulatory T-cells.

Engage natural regulatory T cells via MHC class II and specific TCRs to induce regulatory phenotypes characterized by CD4+CD25+FOXP3.

Increase IL-10 and TGF-β.

Suppress effector cytokines such as IFN-γ and IL-4/IL-5.

Documented Applications

Therapeutic use for autoimmunity, allergy, transplantation/GVHD, infections, and vaccine design by enabling or suppressing tolerance, as described in the document summary.

Use of chimeric fusion constructs including FVIII-Tregitope (FVIII fusion) and enhanced vaccine delivery Fc constructs with modified Tregitopes, as described in the document summary.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.